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A B S T R A C T
Background: This 4-year retrospective cohort study aimed to establish reference intervals for free triiodothyr-
onine (FT3), free thyroxine (FT4), and thyrotropin (TSH) in premature infants using the Beckman Coulter Unicel
DxI 800 automated immunoassay system.
Methods: Study subjects included 605 preterm infants with a gestational age of 26–36 weeks (corrected:
29–38 weeks). Pearson correlation was used to evaluate the association between hormone levels and gestational
and corrected gestational ages. A nonparametric method was used to establish reference intervals based on
corrected gestational age.
Results: FT3 and FT4 levels were positively correlated with gestational and corrected gestational ages, respec-
tively. TSH levels were slightly negatively correlated with gestational and corrected gestational ages. FT3 sig-
nificantly differed according to corrected gestational age (29–33weeks vs 34–38weeks); however, the difference
was smaller than the reference change value (RCV) for the FT3 test. Thus, we combined the FT3 reference
intervals into a single reference interval: 2.65–4.93 pmol/L (29–38weeks). The reference intervals of FT4 and
TSH were 11.20–24.97 pmol/L (29–38weeks) and 1.01–10.14 mIU/L (29–38weeks), respectively.
Conclusions: Unlike those of full-term infants or adults, the reference intervals established in this study are
applicable in premature infants. These results highlight the importance and complexity of establishing instru-
ment-specific thyroid hormone reference intervals for preterm infants.
1. Introduction
Thyroid dysfunction is among the most common preventable causes
of neonatal neurodevelopmental delay. Because of their immature hy-
pothalamic-pituitary-thyroid axis, immature thyroid hormone synthesis
and metabolism, systemic diseases, and physiological and non-physio-
logical factors such as immature thyroid enrichment and iodine
synthesis, premature infants likely have a wider thyroid hormone re-
ference compared to full-term infants [1]. The use of established re-
ference intervals for full-term infants or even those provided in the
reagent instructions (typically established for adults) results in frequent
and unnecessary retesting and intervention [2]. Mixing of reference
intervals established by different detection systems is also well-known
to be inappropriate. Therefore, it is essential to determine instrument-
specific reference intervals for vulnerable populations such as pre-
mature infants. Chinese guidelines for the diagnosis and treatment of
thyroid disease during pregnancy and postpartum [3] stipulate that
early thyroid hormone screening should be carried out in newborns in
China. Blood samples should be obtained from full-term neonates from
72 h up to 7 days post-birth, and the guidelines recommend delaying
sampling until 7 days post-birth for premature neonates. However, few
studies have examined the reference intervals of thyroid hormones in
preterm infants after the first week of life. It is difficult to obtain a large
number of blood samples from healthy preterm infants. Thus, in this
study, we used the hospital database to obtain preterm infant inpatient
medical records using appropriate screening methods and referred to
the EP28-A3c file [4] revised by the Clinical and Laboratory Standards
Institute (CLSI) of America and International Federation of Clinical
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Chemistry to establish thyroid hormone reference intervals in our re-
gion using the Beckman DxI 800 automated immunoassay system. All
hospitalized premature infants were subjected to venous blood sam-
pling for thyroid hormone testing 7 days after birth.
2. Materials and methods
2.1. Study subjects
Preterm infants born between 2015 and 2018 in the neonatal de-
partment of Women and Children's Hospital, Xiamen city, Fujian
Province of China, were selected. We carefully reviewed the infants'
medical records, which included the basic condition and detailed dis-
ease information, mode of departure from the hospital (e.g., infant
death), and the mother's health condition (e.g., diagnosed endocrine
disease), with a special focus on the discharge summary. The infants
had a gestational age of 26–36weeks and corrected gestational age (i.e.,
gestational age plus age at the time of blood collection) of 29–38weeks.
The blood collection time was> 7 days after birth. In this study, we
defined “normal” preterm birth as a common preterm birth complica-
tion [5]. For infants whose gestational age was> 33weeks, the 5-min
Apgar score should be ≥7; for gestational age≤33weeks, the 5-min
Apgar score should be ≥6. The inclusion criteria for normal premature
infants were a height, weight (between the 10th and 90th percentile of
average birth weight), head circumference, and growth rate appro-
priate for gestational age. Exclusion criteria for infants were as follows:
(1) thyroid abnormalities detected within 7 days of birth and treated
with thyroxine, and clinically suspected of having thyroid diseases
(feeding difficulties and long-term or recurrent jaundice); (2) major
congenital abnormalities or significant clinical evidence of infection,
such as necrotizing enterocolitis, respiratory distress syndrome, in-
traventricular hemorrhage, central nervous system diseases, and sepsis;
(3) extrauterine growth retardation with growth values at or below the
10th percentile of intrauterine growth expectation based on estimated
gestational age; (4) death within one month after birth; and (5) mother
suffering from thyroid disease. These data were evaluated by neonatal
physicians who did not participate in the study and were recorded in
detail in the discharge summary. According to standard clinical pro-
tocols, nearly all mothers (approximately 90%) were administered
prenatal glucocorticoid therapy to promote fetal lung maturation. This
study was approved by the Ethics Committee of Xiamen Women and
Children's Hospital, and all parents gave consent for their infants to
participate in the study.
2.2. Instruments and reagents
A detection system, the UniCel DxI 800 chemiluminometer
(Beckman Coulter, Brea, CA, USA), and its accompanying reagents were
used. Free triiodothyronine (FT3) (kit code A13422), free thyroxine
(FT4) (kit code 33880), and thyrotropin (TSH) (kit code 33820) levels
were determined by conducting a competitive binding immunoassay,
two-step competitive enzyme assay, and two-site enzyme immunoassay
(sandwich method), respectively. We used two different levels of serum
quality controls provided by Beckman. The intra-assay and inter-assay
precision were < 6.25% and < 8.33%, respectively. According to the
Westgard Sigma quality management model [6], when using the total
allowable error in national standard, FT3, FT4 and TSH all levels of the
sigma was> 4. We therefore used the 13S /22S /R4S /41S combination
rules. The project passed the external quality assessment conducted by
the Clinical Testing Center of the Ministry of Health of China and
Clinical Testing Center of Fujian Province. The study was carried out in
strict accordance with standard operating procedures. The accelerator
vacuum tube composed of an inert colloidal material was used to collect
venous blood in the morning. Serum separation was completed within
2 h, and the test was completed within 24 h.
2.3. Methods
2.3.1. Normality analysis and transformation of data
Normality analysis of the data was performed using the skewness-
kurtosis test. When the absolute value of the skewness and kurtosis
was< 1.96-fold of the standard error of the sample, we considered the
distribution as approximately normal. Non-normally distributed data
were transformed by Box-Cox transformation, and normality analysis
was repeated. The λ value in the transformation was obtained by
maximum likelihood estimation.
2.3.2. Elimination of outliers
Tukey's method was used to determine the lower quartile (Q1),
upper quartile (Q3), and interquartile range (IQR) and to eliminate the
data beyond (Q1–1.5 IQR) to (Q3+1.5 IQR) [7]. The cycle was con-
tinued until all outliers were removed.
2.3.3. Grouping of reference intervals
Z-test [8] was used to calculate the Z-values (Formula 1) and Z*
values (Formula 2) as follows:
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where−x1 and −x2 are the means of the two groups, S1 and S2 are the
standard deviations of the two groups, and n1 and n2 are samples from
each group. Grouping criteria were as follows: when |Z| > Z* or
S2 > 1.5 S1 or |S2/(S2 – S1)| < 3. At least 120 cases were required per
group, and those who could not be grouped were combined into one
group. Because the days on which the blood was collected varied
among newborns, and the corrected gestational age may affect the re-
ference intervals of premature infants, the subjects were temporarily
divided into three groups with corrected gestational ages: 29–33,
34–35, and 36–38weeks.
2.3.4. Establishment of biological reference intervals
The nonparametric method was used to establish the reference in-
tervals. In the interval in which 2.5–97.5% of the values were located,
the size of the 95% distribution range was selected to represent the
reference intervals.
2.4. Other statistical analyses
Statistical analyses of the data were performed using SPSS 22.0
statistical software (SPSS, Inc., Chicago, IL, USA) with the skewness-
kurtosis normality test, Box-Cox transformation, outlier elimination,
and Pearson correlation analysis. The mean ± standard deviation
(−x ± S) was used to analyze data conforming to the normal dis-
tribution, while the median (IQR) was used to analyze data that did not
show a normal distribution. P < .05 was considered to indicate a sta-
tistically significant difference.
3. Results
3.1. Demographic results of the study cohort
We extracted 2235 neonatal thyroid data from 2015 to 2018. After
carefully reviewing the medical records according to the inclusion and
exclusion criteria, 605 “normal” preterm infants (361 males and 244
females) were included in the study. The mean (SD) gestational age of
this cohort was 32.7 weeks (2.1). The mean (SD) corrected gestational
age was 34.6 weeks (2.0) at the time of testing. The median age at the
time of testing was 11 days (IQR=9–15). Other demographic char-
acteristics are shown in Table 1.
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3.2. Inclusion data normality analysis and transformation
The skewness-kurtosis test showed that FT3, FT4, and TSH were not
normally distributed. Thus, the variables were converted to a normal
distribution by Box-Cox test. The results are shown in Table 2.
3.3. Correlation analysis results
Pearson correlation analysis showed that FT3 and FT4 were posi-
tively correlated with gestational age and corrected gestational age,
respectively. TSH was negatively correlated with gestational age and
corrected gestational age, and the linear regression coefficient β was
determined, as shown in Table 3.
3.4. Outliers and grouping results of reference intervals
The outliers after normal transformation included five cases in FT3,
two in FT4, and eight in TSH. The Z-test results revealed no significant
difference between the FT3 levels in the group with a corrected gesta-
tional age of 34–35weeks and the group with a corrected gestational
age of 36–38weeks, with all levels showing significant differences from
those in the group with a corrected gestational age of 29–33weeks.
However, we found that the difference in the lower limit of normal and
upper limit of normal of the FT3 hormone between 29 and 33weeks
and 34–38weeks of corrected gestational age (9.5–10.2%) was smaller
than the RCV for the FT3 test (29.4%). Thus, we combined the FT3
reference intervals into a single reference interval (29–38weeks). For
the corrected gestational age, combining the 34–35week group and
36–38week group did not significantly change the reference intervals
for FT4 and TSH; thus, these groups can use a single reference interval.
No group met the criterion of S2/S1 > 1.5 or |S2/(S2 – S1)| < 3, as
shown in Table 4.
3.5. Comparison of reference intervals established in this study with the
reference intervals from Beckman and Roche
The nonparametric ranking method used values of 2.5% and 97.5%
as the lower and upper limits of the reference intervals, respectively.
The reference intervals established in this study showed large differ-
ences from those provided by Beckman (UniCel DxI 800) and Roche
(Cobas e 411) [9], as shown in Table 5.
Owing to the lack of reference intervals for thyroid hormone levels
of premature infants, if a clinician uses the adult reference intervals
provided by Beckman, 581 of 605 infants in this cohort would be
considered to have abnormal levels, which is unreasonable. If the re-
ference intervals established in this study are used, the number of in-
fants who require repeat testing or intervention is reduced to 85.
4. Discussion
According to the recommendations of CLSI, healthy subjects should
be selected and a direct reference method should be used to establish a
reference interval; however, this would be costly. Moreover, samples
must be collected from a vulnerable group of premature infants, which
is difficult to achieve. Because of ethical and practical considerations,
we retrospectively reviewed medical records provided by the hospital
database to identify newborns who were “healthy except for pre-
maturity.” We therefore excluded premature infants who were con-
sidered “relatively unhealthy”, such as those larger or smaller than
gestational age standards and those with extrauterine growth retarda-
tion. The lack of consistency in the definition of “normal” preterm in-
fants made this process difficult. Premature infants are at a higher risk
for certain diseases, and maturity changes in FT4 levels often occur
during the last trimester of pregnancy. Non-thyroid diseases such as
respiratory distress syndrome may affect thyroid hormone levels [10].
Williams et al. [11] reported that delayed sepsis significantly reduced
thyroxine, total triiodothyronine, and thyroxine binding globulin levels.
Furthermore, they found that intraventricular hemorrhage, necrotizing
enterocolitis, and the onset of acute inflammatory cytokine response
affected the thyroid hormone levels and caused thyroid dysfunction. In
our previous study, we also found that maternal thyroid disease was a
risk factor affecting the results of neonatal TSH screening [12]. Some
studies evaluated a cohort comprising both diseased preterm infants
and “normal” preterm infants, which may have increased the reference
interval range [13].
Because of immature thyroid axis development in premature in-
fants, the production and secretion of thyrotropin-releasing hormone in
the hypothalamus are reduced, eventually leading to decreased levels of
total triiodothyronine, thyroxine, and FT4 in preterm infants. However,
within 6–8 weeks after delivery, these levels increase to levels com-
parable to those in full-term infants [14]. We found that FT3 and FT4
levels were positively correlated with gestational and corrected gesta-
tional ages, respectively, and TSH showed a weak negative correlation
with gestational and corrected gestational ages, which is consistent
with the results of some previous studies [15,16]. Because the blood
collection days varied among newborns, some studies [9,17] directly
grouped the gestational age or days at the time of testing or did not
distinguish full-term from preterm infants, which may have affected the
final result. This issue was taken into consideration in our study. We
grouped variables according to the corrected gestational age at the time
of testing and found that FT3 should be grouped by 29–33 and
34–38weeks (the difference was smaller than the RCV), while FT4 and
TSH did not require grouping. We also performed statistical analysis by
gender, consistent with previous literature [16], but there were no
significant differences in hormone levels by gender.
Some studies recommend 11.58–29.60 pmol/L FT4 as a reference
Table 1
Demographic characteristics of the study cohort.
Total number of infants (n) 605
Male/female (n) 361/244
Birth weight, g (mean ± SD) 1923.3 ± 405.5
Length, cm (mean ± SD) 43.5 ± 4.2
Head circumference, cm (mean ± SD) 32.9 ± 2.1
Birth Apgar score at 1 min (mean ± SD) 8.7 ± 1.4
Birth Apgar score at 5 min (mean ± SD) 9.2 ± 0.9
Birth Apgar score at 10min (mean ± SD) 9.3 ± 0.7
Gestational age, weeks (mean ± SD) 32.7 ± 2.1
Corrected gestational age at the time of testing, weeks
(mean ± SD)
34.6 ± 2.0
Age at testing in days, median (IQR) 11 (9–15)
Hospital stay in days, median (IQR) 22 (14–32)
Table 2
Normality analysis of each hormone and Box-Cox transformation results.
Hormone Number of cases (n) Parameter λ Before transformation After transformation
Mean Standard deviation Kurtosis Skewness Mean Standard deviation Kurtosis Skewness
FT3 605 0.53 3.76 0.63 0.482 0.292 1.90 0.34 0.304 0.018
FT4 605 0.15 17.45 3.85 0.303 0.513 3.54 0.34 −0.190 −0.001
TSH 605 0.07 4.03 2.85 12.955 2.909 1.27 0.67 1.017 0.014
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interval for full-term infants [16]; the upper limit of this range is higher
than that found in our research. Some authors [18] reported the normal
TSH concentration at 2–6weeks of age as 1.7–9.1 mIU/L; however, our
TSH range was wider than these values. Zhu et al. [9] provided re-
ference intervals based on the corrected gestational age for the second
week of preterm birth; the ranges for FT3 and FT4 were similar to those
found in our study, but the TSH range was wider (0.68–12.53 mIU/L).
We found no records of outlier removal in their reports, which may
explain the wider reference interval. Our upper and lower limits of FT3
were lower, upper and lower limits of TSH were higher, and range of
FT4 was significantly wider than the reference intervals provided by the
kit.
The elimination of outliers is an indispensable step in establishing
reference intervals. Although the Dixon test is recommended by CLSI as
a method of culling outliers, the EP28-A3c guidelines also point out that
if there are several similar outliers on the same side of the data, they
will mask each other and render the Dixon test less effective. In this
case, the data analyst must calculate the outlier with the smallest dis-
persion to ensure that all outliers can be eliminated. However, the
method for determining the outlier with the smallest dispersion when
using the Dixon test is not described in the EP28-A3c guidelines.
Therefore, we chose the Tukey method, which uses only 50% of the
sample data center to reduce or limit the masking effect of multiple
simultaneous outliers on one side. For this test, we determined the
lower quartile (Q1), upper quartile (Q3), and interquartile range (IQR)
and eliminated the data beyond (Q1–1.5 IQR) to (Q3+1.5 IQR). The
cycle was continued until all outliers were removed.
The comparison between the Beckman and Roche platforms showed
that there are still large differences in neonatal reference intervals es-
tablished for different detection platforms (e.g., TSH: (1.01–10.14) vs
(4.55–20.00)). These differences may be explained as follows. First,
Roche did not distinguish premature and term infants, whose thyroid
hormone levels are different. Second, they did not distinguish corrected
gestational ages. It is well known that thyroid hormone levels are dif-
ferent between the first week of life and at 2–4 weeks of life [19]. Thus,
the reference intervals established by Roche may be wide, which
prompted us to establish laboratory-specific reference intervals for
specific neonatal groups.
There were several limitations to our study. Although we adopted
the most stringent inclusion and exclusion criteria, drugs such as do-
pamine, caffeine, and steroids used to treat premature infants may have
caused transient thyroid dysfunction and affected the test results. Given
that there is currently no consistent interaction report [20–22] and
these drugs are routinely used in common complications of preterm
infants, these factors likely did not affect the reference intervals es-
tablished for this population. We retested some outliers of clinical
concern (i.e., TSH > 20 mIU/L). However, because this was a retro-
spective analysis, we did not retest all outliers. In addition, because of
the large number of subgroups of the inclusion and exclusion criteria,
some premature neonates belonged to multiple subgroups. Although we
have thyroid data for these premature neonates, there are inherent
difficulties in data analysis.
Premature infants have a certain level of hyperbilirubinemia. The
“INTERFERENCES” section of the Beckman instructions states the fol-
lowing: Samples containing up to 20mg/dL (342 μmol/L) bilirubin and
10mg/dL (119 μmol/L) conjugated bilirubin do not affect the con-
centration of free T3 assayed. Samples containing up to 10mg/dL
(171 μmol/L) bilirubin do not affect the concentration of free T4 or TSH
assayed. In our cohort, 67 neonates (11.1%) had higher bilirubin con-
centrations than the upper limit of the interference test, with a median
of 213.7 μmol/L (IQR=192.1–278.7). However, the manufacturer's
instructions did not further elaborate on how hyperbilirubin interferes
with the test. In addition, the purpose of this study was to provide re-
ference intervals for thyroid function assessment in preterm neonates
that can be extended to the entire preterm neonatal population, in
which the proportion of hyperbilirubin should be no different from that
of the study population. Thus, the current clinically available methods
for assessing neonatal thyroid function are inevitably affected by un-
certain effects of hyperbilirubin.
Because the measurements of many laboratories are not yet com-
parable, reference intervals are usually established for each assay and
are considered assay-specific. However, healthcare providers who
Table 3
Correlation of test results of each hormone with gestational age and corrected gestational age.
Hormonea Gestational age Corrected gestational age
r Pb β Pc r Pb β Pc
FT3 0.404 0.000 0.066 0.000 0.410 0.000 0.071 0.000
FT4 0.242 0.000 0.039 0.000 0.148 0.000 0.026 0.000
TSH −0.103 0.011 −0.033 0.011 −0.177 0.000 −0.060 0.000
a Box-Cox transformed result.
b P value of correlation coefficient.
c P value of regression coefficient.
Table 4
Relationship between test results of each hormone and corrected gestational age.
Hormonea Corrected gestational age (weeks) Number of cases (n) Mean Standard deviation Judging criteria
|Z| Z⁎ S2/S1 |S2 / (S2–S1)| Remarks
FT3 ① 29–33 200 1.75 0.30 6.94 4.16 0.98 44.98 ① and ② comparisonb
② 34–35 261 1.95 0.30 2.87 3.87 1.12 9.68 ② and ③ comparison
③ 36–38 139 2.04 0.33 8.27 3.57 0.92 11.00 ③ and ① comparisonb
FT4 ① 29–33 200 3.47 0.33 4.07 4.16 1.03 33.84 ① and ② comparison
② 34–35 262 3.60 0.34 1.87 3.89 0.95 19.18 ② and③ comparison
③ 36–38 141 3.53 0.32 1.77 3.58 1.02 48.52 ③ and ① comparison
TSH ① 29–33 198 1.39 0.66 2.40 4.15 0.92 11.45 ① and ② comparison
② 34–35 262 1.25 0.60 1.16 3.87 1.01 90.93 ② and ③ comparison
③ 36–38 137 1.18 0.61 3.11 3.54 1.08 14.27 ③ and ① comparison
a Box-Cox transformed result.
b |Z| > Z⁎.
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require test results from different laboratories often face challenges
owing to different reference intervals. Thienpont et al. [23] reported a
multiassay method comparison study with clinical serum samples and
target setting with a robust factor analysis method for TSH, which
provided evidence that harmonization may enable manufacturers to
achieve more uniform reference intervals in the near future. The re-
searchers pointed out that a uniform reference interval does not mean
“one size fits all” and may be affected by factors such as age, ethnicity,
and iodine intake. We anticipate that our study of premature infants
will contribute to the uniformity of thyroid hormone assays and better
consistency of future results.
In conclusion, we used the Beckman UniCel DxI 800 immunoassay
system to establish reference intervals for FT3, FT4, and TSH after one
week of birth in preterm infants in our region. These reference intervals
were significantly different from those of term infants and those pro-
vided with the kit. Furthermore, these results can be used to avoid
unnecessary retesting and intervention of preterm infants and will be
valuable for clinical evaluation of thyroid function in preterm infants
and differential diagnosis of thyroid diseases.
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Manufacturer reference intervals 0–30 days
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FT4 (pmol/L) 11.20–24.97 7.85–14.40 8.50–39.80
TSH (mIU/L) 1.01–10.14 0.34–5.60 4.55–20.00
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